Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

108.23 +6.09 (+5.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
65 66 Next >
What's Going On With BioNTech (BNTX) Shares?
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading lower by 5.6% to $93.10 Wednesday afternoon. 
Via Benzinga
Pfizer Issues FY24 Forecast, Joins Target Hospitality, Southwest Airlines And Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Shares of Pfizer Inc. (NYSE: PFE) shares fell sharply during Wednesday’s session after the company... 
Via Benzinga
Topics Stocks
Exposures US Equities
Pfizer Stock Tumble Steepens As Seagen Guidance Update Disappoints
Pfizer's updated 2024 revenue figures, including Seagen, undercut the consensus target. 
Via Investor's Business Daily
What's Going On With Moderna Stock Today?
Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and  
Via Benzinga
BioNTech to Inaugurate First African Site on December 18, 2023
From BioNTech SE
Via GlobeNewswire
6 Analysts Have This to Say About BioNTech
Via Benzinga
Analyst Ratings for BioNTech
Via Benzinga
BioNTech Stock Downgraded, Analyst Reflects Concerns Over Growth and Pipeline Development
J.P. 
Via Benzinga
Lululemon To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Dell Reports Mixed Q3 Results, Joins Marvell Technology, Super Micro Computer And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded higher this morning, with the Dow Jones futures gaining more than 80 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is COVID-19 Vaccine Maker Moderna Stock Trading Lower Today?
Moderna Inc (NASDAQ: MRNA) shares slipped on Tuesday trading after the European Patent Office said a contested mRNA patent owned by Moderna is invalid, marking a victory for Pfizer Inc (NYSE: PFE) /  
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
3 Biotech Stocks You’ll Regret Not Buying Soon: November 2023
The global biotechnology market could nearly triple by 2030. Investors should consider buying these biotech stocks before they explode. 
Via InvestorPlace
Monday.Com To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
Eccogene, a Shanghai-Boston biotech, out-licensed global rights (ex-China) for its novel small molecule GLP-1 agonist to AstraZeneca in a $2 billion blockbuster deal. Eccogene will receive $185 million... 
Via Talk Markets
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor. 
Via InvestorPlace
Topics Economy
Exposures Economy
Mohamed El-Erian On Yield And Oil Price Drop: Economic Boon Or Major Downturn Ahead?
Via Benzinga
BioNTech Se (BNTX) Q3 2023 Earnings Call Transcript
BNTX earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Eli Lilly, Power Generators Lead Top S&P 500 Performers Monday
Eli Lilly jumped, while energy plays were big winners and losers. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
BioNTech Stock Surges On Surprise Profit, Strong Sales. But Report Has Downside.
The company was expected to report a third-quarter loss and plummeting sales. 
Via Investor's Business Daily
Crude Oil Moves Higher; BioNTech Lowers 2023 Sales Outlook
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 40 points on Monday The Dow traded up 0.13% to 34,106.99 while the NASDAQ rose 0.16% to 13,499.42. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Like Moderna, BioNTech Cuts Annual Sales Forecast By 20% As Pandemic Fades
BioNTech SE (NASDAQ: BNTX) has reported Q3 revenues of €895.3 million ($974.49 million), sharply down from €3.461 billion a year ago. 
Via Benzinga
US Stocks Set To Extend 5-Day Winning Streak Today? Traders Anxiously Watch Fed Speech, Climbing Bond Yields
The market looks set to extend last week’s gains, with the stock futures holding up early Monday ahead of a slew of earnings reports mostly from the small and mid-cap space. 
Via Benzinga
Topics Economy
Exposures Interest Rates
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Moderna Beats Sales Forecasts, But Light Guidance Could Rattle Shares
The company issued below-consensus sales views for 2023 and 2024. 
Via Investor's Business Daily
3 No-Brainer Stocks to Buy for Under $100 Right Now
A couple of these stocks might not be available for under $100 for too much longer. 
Via The Motley Fool
7 Undervalued Stocks That Analysts Love Right Now
With many investors concerned about what may lie ahead in the market, these potentially de-risked undervalued stocks may be ideal. 
Via InvestorPlace
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
From Pfizer Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.